Mail

UK markets closed

FTSE 100
8,213.49
+41.34(+0.51%)
FTSE 250
20,164.54
+112.21(+0.56%)
AIM
771.53
+3.42(+0.45%)
GBP/EUR
1.1652
-0.0031(-0.26%)
GBP/USD
1.2546
+0.0013(+0.11%)
Bitcoin GBP
50,480.00
+402.43(+0.80%)

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Arbutus Biopharma Corporation (I9DN.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR

Add to watchlist

2.4540

-0.1220

(-4.74%)

At close: 08:06AM CEST

Currency in EUR

Valuation measures⁴

Market cap (intra-day)	455.07M
Enterprise value	339.28M
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	25.26
Price/book (mrq)	4.69
Enterprise value/revenue	18.70
Enterprise value/EBITDA	-4.78

Trading information

Stock price history

Beta (5Y monthly)	N/A
52-week change ³	6.00%
S&P500 52-week change ³	22.38%
52-week high ³	2.9380
52-week low ³	1.5540
50-day moving average ³	2.5219
200-day moving average ³	2.0832

Share statistics

Avg vol (3-month) ³	221
Avg vol (10-day) ³	16
Shares outstanding ⁵	180.18M
Implied shares outstanding ⁶	185.44M
Float ⁸	113.31M
% held by insiders ¹	22.29%
% held by institutions ¹	41.51%
Shares short ⁴	N/A
Short ratio ⁴	N/A
Short % of float ⁴	N/A
Short % of shares outstanding ⁴	N/A
Shares short (prior month ) ⁴	N/A

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Mar 2024

Profitability

Profit margin	0.00%
Operating margin (ttm)	-1,252.15%

Management effectiveness

Return on assets (ttm)	-29.31%
Return on equity (ttm)	-57.54%

Income statement

Revenue (ttm)	12.99M
Revenue per share (ttm)	0.08
Quarterly revenue growth (yoy)	-77.10%
Gross profit (ttm)	N/A
EBITDA	-78.66M
Net income avi to common (ttm)	-74.39M
Diluted EPS (ttm)	-0.3900
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	129.24M
Total cash per share (mrq)	0.74
Total debt (mrq)	8.08M
Total debt/equity (mrq)	7.05%
Current ratio (mrq)	6.70
Book value per share (mrq)	0.65

Cash flow statement

Operating cash flow (ttm)	-77.93M
Levered free cash flow (ttm)	-45.96M